







The ZyCoV-D vaccine heralds a wave of DNA vaccines for various diseases that are undergoing clinical trials around the world.
The 300-year journey to the covid vaccine: From inoculation to RNA
The history of immunization technology is a quest to achieve immunity with ever-more safety and ever-fewer side effects
If we don’t change course, most people in the U.S. will have some flavor of Long COVID of one sort or another — Belshaw Brain Archive
For the past few years, I've been on the list of 'vulnerable' people who get a free booster Covid vaccine due to my asthma. That's no longer the case, but Covid is still around, and mutating
What to Know About New Covid Vaccines for Fall 2026
The shots have been approved for people 65 and older, and for younger people with underlying conditions. Others may be able to get them off label.

Everything You Need to Know About Arcturus, the New COVID Variant
Infectious disease experts weigh in on this new variant rapidly spreading in India.

COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season
This Special Communication aims to identify and summarize the most recently published evidence evaluating the effectiveness and safety of US-licensed COVID-19 vaccines and report on the epidemiology of SARS-CoV-2 in the US.

FDA approves first mRNA-based flu vaccine | CNN
The US Food and Drug Administration on Wednesday approved the United States’ first mRNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.

COVID-19 #CoronaVirus Infographic Datapack — Information is Beautiful
Updated daily, now with global vaccination stats

A New Hantavirus Vaccine Is in the Works
Since 2023, Moderna and Korea University have been developing a new mRNA vaccine for hantavirus. The work has been promising so far, but a finished product isn't likely coming any time soon.

Vascular and inflammatory diseases after COVID-19 infection and vaccination in children and young people in England: a retrospective, population-based cohort study using linked electronic health records
Children and young people have higher risks of rare vascular and inflammatory diseases up to 12 months after a first COVID-19 diagnosis and higher risk of rare myocarditis or pericarditis up to 4 weeks after a first BNT162b2 vaccine, although the risk following vaccination is substantially lower than the risk following infection. These findings are of great importance for national policy makers and caregivers considering vaccination consent for children, and support the public health strategy of COVID-19 vaccination in children and young people to mitigate the more frequent and persistent risks associated with SARS-CoV-2 infection.

Vascular and inflammatory diseases after COVID-19 infection and vaccination in children and young people in England: a retrospective, population-based cohort study using linked electronic health records
Children and young people have higher risks of rare vascular and inflammatory diseases up to 12 months after a first COVID-19 diagnosis and higher risk of rare myocarditis or pericarditis up to 4 weeks after a first BNT162b2 vaccine, although the risk following vaccination is substantially lower than the risk following infection. These findings are of great importance for national policy makers and caregivers considering vaccination consent for children, and support the public health strategy of COVID-19 vaccination in children and young people to mitigate the more frequent and persistent risks associated with SARS-CoV-2 infection.

Inside the body, the coronavirus is even more sinister than scientists had realized
Cells hijacked by the coronavirus grow long, streaming tentacles to reach out to new victims, scientists found. This could complicate the search for a vaccine.
Vaccination Dramatically Lowers Long COVID Risk
Several new studies reveal that getting multiple COVID vaccine doses provides strong protection against lingering symptoms

Why Is Everyone Getting Sick? Behind the Global Rise in RSV, Flu, Measles
It's not your imagination: At least 13 communicable diseases are surging past pre-pandemic levels

COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season
Importance SARS-CoV-2 remains a substantial cause of respiratory illness, morbidity, and mortality. Evidence to date has demonstrated that COVID-19 vaccines reduce the risk of severe disease, including hospitalization and death. Objective This systematic review identifies and summarizes newly published studies reporting on the effectiveness and safety of COVID-19 vaccines and COVID-19 epidemiology in the US. Evidence Review Cochrane Central Register of Controlled Trials, PubMed/MEDLINE, Embase, and Scopus were searched from August 1, 2025, through June 29, 2026. Studies were eligible if they reported on the effectiveness, efficacy, or safety of a US-licensed COVID-19 vaccine or SARS-CoV-2 epidemiology in the US. Findings From 11 829 identified references, 155 publications were eligible (15 randomized clinical trials, 84 observational studies with a comparator group, 38 product safety studies without a comparator group [single group], and 18 descriptive studies of disease burden). Consistent with prior evidence, studies reported that updated COVID-19 vaccines were associated with a reduction in the risk of hospitalization among both older adults (≥65 years; vaccine effectiveness [VE], 53.0%; 95% CI, 37.0%-65.0%; 2025-2026 season) and adults (18-64 years; VE, 54.0%; 95% CI, 1.0%-78.0%; 2024-2025 season). Maternal vaccination was associated with reduced risk of COVID-19–associated emergency department/urgent care encounters among individuals vaccinated (VE, 58.0%; 95% CI, 24.0%-77.0%) and with fewer COVID-19–related hospital contacts in the first 2 months of life among infants born subsequently (VE range, 50.0%-54.0%), regardless of trimester of vaccination. Vaccination was also associated with a significant reduction in COVID-19–related pediatric emergency department visits (9 months to 4 years; VE, 76.0%; 95% CI, 58.0%-87.0%). Vaccination was associated with a reduced risk of critical COVID-19 illness (intensive care unit admission or death) in immunocompromised adults (VE range, 32.0%-53.0%, depending on condition and other factors). Health care personnel who received 3 to 5 vaccine doses were less likely to develop laboratory-confirmed COVID-19 illness (VE, 41.0%; 95% CI, 34.0%-47.0%) and postacute COVID-19 symptoms (VE, 57.0%; 95% CI, 46.0%-66.0%) compared with those who received only 2 doses. Across adverse events of special interest (eg, stroke, thrombosis, myocarditis), safety profiles were consistent with those of previous reviews. No identified studies conducted under the updated guidance on extended dosing intervals for the primary series reported an increased risk of myocarditis or pericarditis. No new safety signals were reported in the recently published studies eligible for this updated review of US-licensed COVID-19 vaccines. Conclusions and Relevance COVID-19 vaccines were consistently associated with a reduction in the risk of hospitalization and other outcomes, including among individuals at high risk of severe COVID-19, such as infants, and those who were pregnant. No new safety concerns were identified.

Japan: A study covering 2020–2023 estimated COVID-19 infections were 4.7x higher than officially reported. During Omicron BA.4/5: • Reinfection rate rose from 0.4% (2021) to 28.1% (2023) • Reinfections made up 81.5% of new infections • Findings highlight widespread underreporting and reinfections

COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season

BMJ Group retracts paper on COVID-19 vaccines and mortality featured in Senate hearing

What to Know About New Covid Vaccines for Fall 2026
Underlying Conditions and the Higher Risk for Severe COVID-19